Neutrophil trafficking (MRP2/FPR1)

Class

Neutrophil trafficking modulator

This mechanism targets the formyl peptide receptor 1 (FPR1), a cell-surface receptor found predominantly on neutrophils, a type of white blood cell that responds rapidly to infection and tissue injury. FPR1 senses formylated peptides released by bacteria and by damaged host cells, and its activation drives neutrophils to migrate toward sites of inflammation, a process called chemotaxis, where they release reactive molecules and enzymes intended to clear pathogens. In chronic inflammatory diseases of the gut, such as inflammatory bowel disease, this same recruitment process becomes self-perpetuating: neutrophils accumulate in the intestinal mucosa and contribute to ongoing tissue damage rather than resolving infection. Blocking FPR1 aims to reduce this excessive neutrophil trafficking into inflamed tissue. A distinguishing feature of this approach is pairing FPR1 modulation with a gut-restricted design, achieved by exploiting MRP2 (multidrug resistance-associated protein 2), an efflux transporter expressed in intestinal epithelial cells that pumps compounds back into the gut lumen rather than allowing them into the bloodstream. This combination is intended to concentrate the anti-inflammatory effect locally in the intestine while limiting systemic exposure and the broader immune suppression that a circulating FPR1 antagonist might otherwise cause.